Observational analysis reveals curcumin's effectiveness in alleviating inflammation in ulcerative colitis, indicating potential for improved treatment options.
The current consensus is that combating reactive oxygen species (ROS) and implementing site-specific drug delivery are effective strategies for managing ulcerative colitis (UC). Herein, ferulic acid (FA) was used to fabricate curcumin (CUR) derivative polymer nanoparticles (CURDNPs) as a delivery vehicle for CUR, forming CURDNPs@CUR. This system enhances the dispersion, bioavailability, UV protection, and controlled-release performance of CUR while also improving its ROS-eliminating activity. In dextran sulfate sodium salt (DSS)-treated mice, CURDNPs@CUR delivers curcumin specifically to the colon, boosts antioxidant enzyme activity, and significantly ameliorates colon histopathology. It reduces the expression of pro-inflammatory cytokine genes (TNFα, NLRP3, and iNOS) and restores intestinal epithelial integrity by decreasing intestinal permeability and enhancing the expression of tight junction proteins (TJPs), including ZO-1, Occludin-1, and Claudin-1. These findings suggest the successful synthesis of a targeted/antioxidant CUR delivery vehicle for synergistic UC therapy via ROS elimination, barrier repair, and anti-inflammation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: